Ibere Pharmaceuticals Net Tangible Assets

The latest net tangible assets for IBER is $130M as of September 2022. That compares with $130M in the prior-year period — up 4.9% year over year. Investors often review this figure alongside Ibere Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, IBER's net tangible assets moved from $130M to $130M — a 4.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Ibere Pharmaceuticals's operating scale or balance-sheet position.

A net tangible assets figure of $130M for IBER is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting IBER's net tangible assets ($130M), review year-over-year change from $130M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.